Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary

Chronic Obstructive Pulmonary Disease Clinical Trial

— MESA-COPD  

Official title:

Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01397721
• Other study ID #: AAAD6395
• Secondary ID: R01HL093081-01
• Status: Active, not recruiting
• Phase: N/A
• First received: July 13, 2011
• Last updated: April 22, 2015
• Start date: May 2009
• Est. completion date: July 2016

Study information

• Verified date: April 2015
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease (COPD) Study aims to characterize the pulmonary vascular changes and their biology in early COPD using imaging, gene expression profiling and peripheral cellular measures.

Description:

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the US and will soon replace stroke as the third leading cause.

Translation of promising biological hypotheses of COPD pathogenesis to human populations that may lead to new therapies is urgently needed. The vascular hypothesis of COPD was articulated almost 50 years ago. Bench research on endothelial dysfunction in COPD is evolving rapidly and has shown that acrolein in cigarette smoke causes endothelial apoptosis and endothelial apoptosis is directly implicated in COPD pathogenesis. Clinical studies on endothelial dysfunction and vascular changes in COPD are limited.

The proposed study is a longitudinal study of smokers nested among the MESA-Lung (AAAA7791) and EMphysema and Cancer Action Project (EMCAP) Studies (AAAA6484), which together provide a well-defined cohort of 4,617 participants with prior spirometry and CT measures.

The Multiethnic Study of Atherosclerosis - Chronic Obstructive Pulmonary Disease (MESA COPD Study) has two main scientific purposes:

1. characterize the pulmonary vascular changes in COPD and their biology, and

2. propose novel pathways for new therapies in COPD.

MESA COPD is a longitudinal study of smokers nested within the MESA-Lung and EMCAP cohorts of 360 participants (160 cases with mild, 60 cases with moderate and 40 cases with severe COPD and 100 controls) who will be phenotyped with magnetic resonance (MR) pulmonary angiography, pulmonary function testing, full-lung CT scans, serum Vascular Endothelial Growth Factor (VEGF), cell assays and gene expression profiling. MESA COPD Study will contribute improving the knowledge of early changes in COPD that may lead to novel disease-modifying medical therapies and preventative strategies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 360
• Est. completion date: July 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 79 Years

Eligibility

Inclusion Criteria:

• age 50-79 years at time of enrollment

• ever smokers (10 or more pack-years)

• participation in MESA or EMCAP studies

Exclusion Criteria:

• clinical cardiovascular disease (left congestive heart failure (CHF), valve disease, coronary artery disease (CAD), stroke, or congenital heart disease),

• asthma, pulmonary embolism or lung disease other than COPD,

• weight > 300 lbs,

• chronic renal insufficiency ([estimated glomerular filtration rate (eGFR)] < 45 mL/min/1.73 m2),

• cancer,

• atrial fibrillation, and

• contraindications to magnetic resonance imagine (MRI), gadolinium, albuterol or spirometry testing.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Locations

Country	Name	City	State
United States	Columbia University	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in cardiac structure and pulmonary vascular structure and function	Cardiac structure: changes in right ventricular (RV) mass, RV mass/Right Ventricular End-Diastolic Volume (RV-EDV); Pulmonary structure: changes in total pulmonary vascular volume (TPVV) and pulmonary artery (PA) perfusion; Function: changes in PA flow and distensibility	Up to 2 years from start of study	No
Secondary	Numbers of CD31+/CD42 endothelial microparticles (EMPs)	Numbers of CD31+/CD42 EMPs reflective of apoptosis are elevated; They are abnormal in severe, moderate and mild COPD compared to controls.	Up to 2 years from the start of study	No
Secondary	Numbers of circulating endothelial cells (CEC)	Numbers of circulating endothelial cells (CEC), resulting from endothelial injury, are elevated. They are abnormal in severe, moderate and mild COPD compared to controls	Up to 2 years from the start of study	No
Secondary	Numbers of endothelial progenitor cells (EPCs), involved in endothelial repair, are decreased	They are abnormal in severe, moderate and mild COPD compared to controls.	Up to 2 years from the start of study	No

External Links

•   Related Info